Zacks: Analysts Anticipate Intec Pharma Ltd (NTEC) to Announce -$0.19 Earnings Per Share

Equities analysts expect that Intec Pharma Ltd (NASDAQ:NTEC) will announce ($0.19) earnings per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Intec Pharma’s earnings. Intec Pharma reported earnings of ($0.32) per share in the same quarter last year, which suggests a positive year over year growth rate of 40.6%. The firm is scheduled to issue its next earnings results on Friday, April 6th.

According to Zacks, analysts expect that Intec Pharma will report full year earnings of ($1.35) per share for the current fiscal year. For the next fiscal year, analysts expect that the company will post earnings of ($0.89) per share. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Intec Pharma.

A number of research firms have commented on NTEC. Zacks Investment Research raised shares of Intec Pharma from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a research report on Saturday. CIBC reaffirmed an “outperform” rating and issued a $15.00 price target (up previously from $10.00) on shares of Intec Pharma in a research note on Thursday, September 21st. Oppenheimer set a $15.00 target price on Intec Pharma and gave the stock a “buy” rating in a research note on Friday, October 13th. ValuEngine cut Intec Pharma from a “hold” rating to a “sell” rating in a report on Thursday, November 16th. Finally, Maxim Group set a $8.00 price target on Intec Pharma and gave the stock a “buy” rating in a report on Friday, November 17th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $11.15.

A number of hedge funds and other institutional investors have recently modified their holdings of NTEC. Caxton Corp purchased a new stake in shares of Intec Pharma in the 3rd quarter valued at about $681,000. Pura Vida Investments LLC purchased a new position in Intec Pharma in the 3rd quarter worth approximately $895,000. Sectoral Asset Management Inc bought a new stake in shares of Intec Pharma in the 3rd quarter worth approximately $3,177,000. Finally, Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Intec Pharma by 5.0% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 522,200 shares of the biotechnology company’s stock worth $2,977,000 after buying an additional 25,000 shares during the last quarter. Institutional investors and hedge funds own 40.16% of the company’s stock.

Intec Pharma (NTEC) opened at $6.80 on Wednesday. Intec Pharma has a 52 week low of $4.20 and a 52 week high of $9.80.

ILLEGAL ACTIVITY WARNING: This article was first posted by BBNS and is the sole property of of BBNS. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://baseballnewssource.com/markets/zacks-analysts-anticipate-intec-pharma-ltd-ntec-to-announce-0-19-earnings-per-share/1822311.html.

Intec Pharma Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Get a free copy of the Zacks research report on Intec Pharma (NTEC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.